Alizyme has a late stage, diversified portfolio of competitive products for the treatment of obesity and type 2 diabetes, ulcerative colitis and mucositis.

20 Nov 08
London Stock Exchange

10.50 GBp

Change -0.75

(20 minutes delayed)


24/07/08
COLAL-PRED®Phase III Clinical Trial Presentation

24/07/08
Replay of the webcast of the Analyst Meeting announcing the results of its European Phase III clinical trial of COLAL-PRED® , which took place at 11:00am (GMT) on Thursday 24th July 2008.

19/11/08
Interim Management Statement

16/09/08
Takeda Milestone Payment

05/09/08
Update on Board Change

29/08/08
Interim Report 2008

09/04/08
Annual Report & Accounts 2007